Deciphering the Enigma: A Comprehensive Approach to Unexplained Weight Loss in Clinical Practice
OthersPage Navigation
Introduction
Unexplained weight loss (UWL), defined as a loss of 5% or more of total body weight within a six-month period, poses a diagnostic challenge in clinical practice. While it can be a harbinger of serious underlying pathology, it often remains unexplained despite thorough investigation.
Etiology and Clinical Evaluation
UWL can be attributed to gastrointestinal disorders, malignancies, psychiatric conditions, endocrine disorders, or chronic infections. The initial evaluation should include a comprehensive history, physical examination, and basic laboratory tests. If these are inconclusive, further targeted investigations may be required based on the patient's history and clinical presentation.
Role of Imaging and Specialized Tests
Imaging studies, such as CT scans or MRIs, can be useful in detecting occult malignancies or other abnormalities. Specialized tests, such as endoscopy or colonoscopy, may be warranted in cases of suspected gastrointestinal disorders. However, these should be guided by the patient's symptoms and risk factors, to avoid unnecessary investigations.
Management and Follow-Up
Management depends on the underlying cause. Even if no cause is identified, it is important to monitor the patient closely, as the cause may become apparent over time. Nutritional support should be provided to all patients experiencing UWL, to prevent further weight loss and associated complications.
Conclusion
UWL is a complex clinical problem that requires a systematic approach for effective management. While it can be frustrating when no cause is found, clinicians should remain vigilant, as early detection of serious underlying conditions can significantly impact patient outcomes.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge